NCT01157156已完成1 期
A Phase I, Multi-Center, Open Label, Safety and Tolerability Study of Single and Repeated Administrations of Escalating Dose(s) of NV1FGF Administered by Intra-Muscular Injection in Patients With Severe Peripheral Artery Occlusive Disease
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 51
- 试验地点
- 2
- 主要终点
- Safety assessment (adverse events, physical examination,vital signs,ECG, laboratory tests...)
研究概览
简要总结
The primary objective is to evaluate safety and tolerability of single and repeated administrations of escalating doses of NV1FGF administered intramuscularly in patients with severe Peripheral Artery Occlusive Disease (PAOD), (Rutherford's Grade II, category 4 or Grade III, category 5 and 6).
Secondary objectives are:
- To determine the biological activity of NV1FGF on collateral artery development.
- To evaluate the activity of NV1FGF on hemodynamic and clinical parameters.
详细描述
Screening period of 30 days before dosing. Patients receive a single administration or repeated (2) administrations (with a 2-week interval) of NV1FGF. Patients are then followed for a period of 6 months
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Severe PAOD defined as Rutherford's Grade II, category 4 or Grade III, category 5 and 6
- •Pain at rest for at least 2 weeks duration and/or trophic lesions for at least the previous 14 days with no signs of healing (no reduction in ulcer size or depth)
- •Objective evidence of peripheral vascular disease (resting Ankle Brachial Index < 0.4 and/or resting Toe Brachial Index < 0.3 and/or metatarsal Peripheral Vascular Resistance flat or barely pulsatile in the diseased limb on 2 consecutive examinations performed at least 2 weeks apart)
- •Angiographic demonstration of total occlusion of the affected limb of one or more of the iliac, superficial femoral, popliteal and/or one or more infrapopliteal arteries
- •Poor candidate for surgical intervention or revascularization procedures (no tibial artery incontinuity as defined from mid-leg distance from the foot and no autologous tissue available)
排除标准
- •Previous or current history of malignant disease. Patients who had successful tumor resection more than 10 years prior to inclusion into the study and had no recurrence and patients who had curatively resected basal/squamous cancer of the skin were allowed for inclusion
- •Abnormal chest X-ray with suspected malignant tumor presence
- •Positive stool hemoccult (expect if due to hemorrhoids)
- •Positive Prostate Specific Antigen for men with suspected malignant tumor presence
- •Abnormal mammography for women with suspected malignant tumor presence
- •Papanicolaou smear (for women) of Class IV or Class V characterization
- •Proliferative retinopathy
- •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
结局指标
主要结局
Safety assessment (adverse events, physical examination,vital signs,ECG, laboratory tests...)
时间窗: 12 weeks
次要结局
- ulcers healing assessment (length, width, type, depth)(12 weeks)
- pain assessment (self-administered visual analog scale)(12 weeks)
- hemodynamic parameters (TcPO2, Ankle Brachial Index, Toe Brachial Index, pulse volume recording) and angiography(12 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)LymphomaNCT00517530Hoffmann-La Roche134
已完成
1 期
Trial Of IW001 in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisNCT01199887ImmuneWorks30
已完成
1 期
Study to Evaluate the Safety, Tolerance, Pharmacokinetics Characteristics of PA3670 Tablets in Chinese Healthy SubjectsChronic HBV InfectionNCT05851261Zhejiang Palo Alto Pharmaceuticals, Inc.60
已完成
1 期
Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain TumourBrain TumorRecurrent GlioblastomaNCT00503204AstraZeneca20
招募中
1 期
A Study of SHR-3821 Injection in Subjects With Advanced Solid TumorsAdvanced Solid TumorsNCT06618651Suzhou Suncadia Biopharmaceuticals Co., Ltd.162